Evidence map›Paper›PMID 28915609›Full record

ArticleOncotarget2017

Polymorphisms of pri-miR-219-1 are associated with the susceptibility and prognosis of non-small cell lung cancer in a Northeast Chinese population.

Chang Zheng, Xuelian Li, Lingzi Xia, Xue Fang, Xiaowei Quan, Zhihua Yin, Yuxia Zhao, Baosen Zhou

Abstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Roles of HOTAIR in lung cancer susceptibility and prognosis.Molecular genetics & genomic medicine · 2020
    Article
  5. Influence of variants of theAmerican journal of translational research · 2020
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chang ZhengDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Xuelian LiDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Lingzi XiaDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Xue FangDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Xiaowei QuanDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Zhihua YinDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Yuxia ZhaoDepartment of Radiotherapy, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Baosen ZhouDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Occurrence and development of non-small cell lung cancer (NSCLC) is a complex process affected both by gene and environment. Single nucleotide polymorphisms (SNPs) in microRNAs' (miRNAs) biogenesis influenced the expression of mature miRNAs, further had an impact on risk of NSCLC. Our study focused on the correlation between rs213210, rs421446 or rs107822 polymorphisms in pri-miR-219-1 and susceptibility or prognosis of NSCLC in Chinese. A case-control study of 405 new-diagnosis patients and 405 controls was performed. Ten ml venous blood from each subject was collected for genotype test via using TaqMan allelic discrimination methodology and SPSS was performed for statistical analyses. We found that CC genotype in rs213210 (OR=3.462, 95%CI=2.222-5.394,

Indexed as

miRNANSCLCprognosisSNPsusceptibility

Identifiers

PMID28915609
PMCPMC5593580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.